Condition: GIST - Gastrointestinal Stromal Tumor · GIST · GIST Metastatic Cancer · Sponsor: Kumquat Biosciences Inc.
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.
This description comes directly from the study's public registry record.
Kumquat Clinical Development · 858-214-2700 · kumquatstudies@kumquatbio.com
Always discuss trial participation with your own doctor first.
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Mayo Clinic - Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| University of Iowa Health Care | Iowa City, Iowa, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Hospitals | Ann Arbor, Michigan, United States | Recruiting |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | Recruiting |
| Northwell Health/R.J. Zuckerberg Cancer Center | Lake Success, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07406633